GlassScriptPhysician profile
James L Burns
NPI 1235118803
$9,098.55
in general payments reported to CMS, 2019-2025
37 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,068 · 2020: $2,807 · 2021: $3,128 · 2022: $95.20.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,685.64 | 2019-2021 | |
| Abbvie INC. | $1,135.19 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $891.76 | 2019-2022 | |
| Janssen Biotech, INC. | $741.39 | 2019-2022 | |
| Lilly USA, LLC | $570.57 | 2019-2021 | |
| Ucb, INC. | $565.42 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $461.77 | 2019-2021 | |
| Pfizer INC. | $452.56 | 2019-2022 | |
| Glaxosmithkline, LLC. | $354.79 | 2019-2021 | |
| Horizon Therapeutics Plc | $306.63 | 2019-2021 | |
| Radius Health, INC. | $233.42 | 2019-2021 | |
| Genzyme Corporation | $200.21 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $195.46 | 2019 | |
| Genentech USA, INC. | $164.86 | 2019-2022 | |
| Celgene Corporation | $155.07 | 2019 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $113.71 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.74 | 2019 | |
| Sobi, INC | $85.57 | 2019-2021 | |
| Acadia Pharmaceuticals INC | $77.60 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $70.53 | 2021 | |
| Gilead Sciences, INC. | $62.74 | 2020 | |
| Antares Pharma, INC. | $60.54 | 2019-2020 | |
| Janssen Scientific Affairs, LLC | $59.18 | 2019-2020 | |
| Neurelis, INC. | $48.46 | 2020 | |
| Mallinckrodt Hospital Products INC. | $47.94 | 2021 | |
| Hikma Pharmaceuticals USA | $44.26 | 2019 | |
| Neurocrine Biosciences, INC. | $43.09 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $38.54 | 2019-2020 | |
| Aurinia Pharma U.S., INC. | $30.49 | 2021 | |
| Daiichi Sankyo INC. | $21.31 | 2021 | |
| Portola Pharmaceuticals, LLC | $17.00 | 2020 | |
| Mallinckrodt Enterprises LLC | $14.20 | 2019 | |
| Assertio Therapeutics, INC. | $13.70 | 2019 | |
| Redhill Biopharma INC. | $13.19 | 2021 | |
| Alexion Pharmaceuticals, INC. | $11.97 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $11.08 | 2021 | |
| Zyla Life Sciences, INC. | $10.97 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Burns listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.